Home › Trigeminal Neuralgia › NCT06216886
OnabotulinumtoxinA for Trigeminal Neuralgia
RecruitingPhase 4
Randomized Controlled Trial of Intradermal Injections of OnabotulinumtoxinA vs Saline for Trigeminal Neuralgia.
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: Men and women age 18 or older * Judged to be of legal competence * Sufficient knowledge of written and spoken English * Capable of attending regular in-person visits * Have failed/not a candidate/do not want surgery * Inadequate response to medication - at least 2 trials * Meeting ICHD criteria for Classical Trigeminal Neuralgia 13.1.1.1 * Patients with frequency \> 10 attacks per week * Stable dose of medications in the last 2 weeks Exclusion Criteria: * Secondary or Idiopathic TN, or Painful Trigeminal Neuropathy as defined by the ICHD (13.1.1.2, 13.1.1.3, 13.1.2) * Pregnant or breast feeding (while it is rare that a patient will be pregnant with TN, there is not sufficient data to say definitively that onabotA is ok to use during pregnancy and nursing, it is still rated Class C) * Neuromuscular disease * On aminoglyocosides * Not currently enrolled in any other studies
About the study
A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.
What is being tested
- OnabotulinumtoxinA 100 UNT [Botox] (drug)
- Sodium Chloride 0.9% for Injection, Preservative Free (drug)
Sponsor: Stanford University · Participants: 20 · Started: Jun 1, 2024
Contact the study team
- Meredith Barad, MD · Phone: 6507217218
- Natali Ariyoshi · Phone: 6504978821
Official record on ClinicalTrials.gov — NCT06216886
Locations in the U.S.
| California | Meredith Barad, Stanford |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.